Pure Global

Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects - Trial NCT04232514

Access comprehensive clinical trial information for NCT04232514 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04232514
Phase 1
Completed
drug
Trial Details
ClinicalTrials.gov • NCT04232514
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects
A Open-label, Single Center Drug Interaction Study Between HEC74647PA Capsule and HEC110114 in Healthy Subjects

Study Focus

Chronic Hepatitis C

HEC74647

Interventional

drug

Sponsor & Location

Sunshine Lake Pharma Co., Ltd.

Changchun, China

Timeline & Enrollment

Phase 1

Jul 15, 2020

Aug 22, 2020

28 participants

Primary Outcome

Adverse Events,Cmax,AUC

Summary

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics
 (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects

ICD-10 Classifications

Chronic viral hepatitis C
Acute hepatitis C
Chronic viral hepatitis
Other chronic viral hepatitis
Chronic hepatitis, unspecified

Data Source

ClinicalTrials.gov

NCT04232514

Non-Device Trial